SEQUENCE
Sequential gilteritinib in combination with venetoclax and azacitidine for patients with newly diagnosed acute myeloid leukemia (AML) and FLT3 mutations ineligible for intensive treatment.
| Studienleiter | Prof. Dr. Christoph Röllig |
| EU CT-Nr. | 2023-507878-41-00 |
| Studientyp | Phase II |
| Indikation | AML |
| ClinicalTrial | NCT06696183 |